Related references
Note: Only part of the references are listed.Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease
Naoki Mizuno et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
Takashi Sasaki et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
Yoshio Sumida et al.
HEPATOLOGY RESEARCH (2019)
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
A. J. Scheen
DIABETES & METABOLISM (2019)
Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
Norio Akuta et al.
HEPATOLOGY RESEARCH (2019)
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Mitsuko Inoue et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
Yuya Seko et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Alessandro Mantovani et al.
DIABETES CARE (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
K. Cusi et al.
DIABETIC MEDICINE (2018)
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
Alessandro Mantovani et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Toshio Itani et al.
OBESITY SCIENCE & PRACTICE (2018)
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko et al.
HEPATOLOGY RESEARCH (2017)
Hepatic fat quantification using the two-point Dixon method and fat color maps based on non-alcoholic fatty liver disease activity score
Tatsuya Hayashi et al.
HEPATOLOGY RESEARCH (2017)
Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
David Goldberg et al.
GASTROENTEROLOGY (2017)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes
Takahiro Tosaki et al.
INTERNAL MEDICINE (2017)
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Bo Kyung Koo et al.
JOURNAL OF HEPATOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
Tisha R. Joy et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Hiroshi Tobita et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
Toshiyuki Hayashi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based On Serial Liver Biopsies
Norio Akuta et al.
HEPATOLOGY COMMUNICATIONS (2017)
A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease
Ilkay S. Idilman et al.
ACTA RADIOLOGICA (2016)
In vivo and ex vivo measurements: noninvasive assessment of alcoholic fatty liver using 1H-MR spectroscopy
Daniel Keese et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2016)
In vivo and ex vivo measurements: noninvasive assessment of alcoholic fatty liver using 1H-MR spectroscopy
Daniel Keese et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2016)
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
Takamasa Ohki et al.
CLINICAL DRUG INVESTIGATION (2016)
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
L. A. Leiter et al.
DIABETES & METABOLISM (2016)
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
A. Dutour et al.
DIABETES OBESITY & METABOLISM (2016)
Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice
Atsushi Obata et al.
ENDOCRINOLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Sarcopenia Is Associated With Significant Liver Fibrosis Independently of Obesity and Insulin Resistance in Nonalcoholic Fatty Liver Disease: Nationwide Surveys (KNHANES 2008-2011)
Yong-ho Lee et al.
HEPATOLOGY (2016)
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Jeffrey Cui et al.
JOURNAL OF HEPATOLOGY (2016)
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Giovanni Targher et al.
JOURNAL OF HEPATOLOGY (2016)
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Srinivasan Dasarathy et al.
JOURNAL OF HEPATOLOGY (2016)
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Deepson S Shyangdan et al.
BMJ Open (2016)
Fructose and uric acid in diabetic nephropathy
Petter Bjornstad et al.
DIABETOLOGIA (2015)
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Sumio Watanabe et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
Masanori Yokono et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients
Takashi Nakahara et al.
JOURNAL OF GASTROENTEROLOGY (2014)
1H MRS assessment of hepatic steatosis in overweight children and adolescents: comparison between 3T and open 1T MR-systems
Elizaveta Chabanova et al.
ABDOMINAL IMAGING (2013)
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
M. J. Armstrong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
G. Musso et al.
DIABETOLOGIA (2012)
Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis
Perry J. Pickhardt et al.
EUROPEAN RADIOLOGY (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study
Yuichiro Eguchi et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
G. Vernon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Kohichiroh Yasui et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
The Development of Chronic Kidney Disease in Japanese Patients with Non-alcoholic Fatty Liver Disease
Yasuji Arase et al.
INTERNAL MEDICINE (2011)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Noreen Hossain et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Amy G. Shah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Solute carrier family 2, member 9 and uric acid homeostasis
Chris Cheeseman
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2009)
Elevated Serum Uric Acid Concentrations Independently Predict Cardiovascular Mortality in Type 2 Diabetic Patients
Giacomo Zoppini et al.
DIABETES CARE (2009)
Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study
Srinivasan Dasarathy et al.
JOURNAL OF HEPATOLOGY (2009)
Quantification of Liver Fat Content: Comparison of Triple-Echo Chemical Shift Gradient-Echo Imaging and in Vivo Proton MR Spectroscopy
Boris Guiu et al.
RADIOLOGY (2009)
Magnetic resonance imaging and spectroscopy for monitoring liver steatosis
Gary J. Cowin et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2008)
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study
S Yusuf et al.
LANCET (2005)
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
V Ratziu et al.
GASTROENTEROLOGY (2005)
Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men -: 13-year follow-up data from the Quebec Cardiovascular Study
AC St-Pierre et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
CT Wai et al.
HEPATOLOGY (2003)
The utility of radiological imaging in nonalcoholic fatty liver disease
S Saadeh et al.
GASTROENTEROLOGY (2002)
A novel method of measuring intra-abdominal fat volume using helical computed tomography
J Kobayashi et al.
INTERNATIONAL JOURNAL OF OBESITY (2002)
Visceral adiposity and risk of type 2 diabetes - A prospective study among Japanese Americans
EJ Boyko et al.
DIABETES CARE (2000)
Share Paper
